Evidence map›Paper›PMID 29357384›Full record

ArticlePLoS pathogens2018

Regional and subtype-dependent miRNA signatures in sporadic Creutzfeldt-Jakob disease are accompanied by alterations in miRNA silencing machinery and biogenesis.

Franc Llorens, Katrin Thüne, Eulàlia Martí, Eirini Kanata, Dimitra Dafou, Daniela Díaz-Lucena, Ana Vivancos, Orr Shomroni, Saima Zafar, Matthias Schmitz and 11 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 32 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 11 institutions in 4 countries.

Franc LlorensDepartment of Neurology, University Medical School, Göttingen, Germany.ORCID 0000-0002-9756-7497
Katrin ThüneDepartment of Neurology, University Medical School, Göttingen, Germany.
Eulàlia MartíCentre for Genomic Regulation, Barcelona, Spain.ORCID 0000-0002-1030-3158
Eirini KanataPrion Diseases Research Group, School of Health Sciences, Department Of Pharmacy, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Dimitra DafouDepartment of Genetics, Development and Molecular Biology, School of Biology, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Daniela Díaz-LucenaCenter for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Barcelona, Spain.
Ana VivancosVall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Orr ShomroniGerman Center for Neurodegenerative Diseases (DZNE), Computational Systems Biology, Göttingen, Germany.
Saima ZafarDepartment of Neurology, University Medical School, Göttingen, Germany.
Matthias SchmitzDepartment of Neurology, University Medical School, Göttingen, Germany.
Uwe MichelDepartment of Neurology, University Medical School, Göttingen, Germany.ORCID 0000-0002-9302-2705
Natalia Fernández-BorgesCentro de Investigación en Sanidad Animal (CISA-INIA), Madrid, Spain.
Olivier AndréolettiInstitut National de la Recherche Agronomique/Ecole Nationale Vétérinaire, Toulouse, France.
José Antonio Del RíoCenter for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Barcelona, Spain.ORCID 0000-0002-5214-4909
Juana DíezMolecular Virology group, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain.
Andre FischerGerman Center for Neurodegenerative Diseases (DZNE), Epigenetics and Systems Medicine in Neurodegenerative Diseases, Göttingen, Germany.
Stefan BonnGerman Center for Neurodegenerative Diseases (DZNE), Computational Systems Biology, Göttingen, Germany.ORCID 0000-0003-4366-5662
Theodoros SklaviadisPrion Diseases Research Group, School of Health Sciences, Department Of Pharmacy, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Juan Maria TorresCentro de Investigación en Sanidad Animal (CISA-INIA), Madrid, Spain.ORCID 0000-0003-0443-9232
Isidre FerrerCenter for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Barcelona, Spain.
Inga ZerrDepartment of Neurology, University Medical School, Göttingen, Germany.
German Center for Neurodegenerative Diseases · DEAristotle University of Thessaloniki · GRBiomedical Research Networking Center on Neurodegenerative Diseases · ESCentro de Investigación en Sanidad AnimalBellvitge University Hospital · ESCentre for Genomic Regulation · ESÉcole Nationale Vétérinaire de Toulouse · FRUniversität Hamburg · DEUniversitat Pompeu Fabra · ESUniversity of Göttingen · DEVall d'Hebron Institute of Oncology · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Increasing evidence indicates that microRNAs (miRNAs) are contributing factors to neurodegeneration. Alterations in miRNA signatures have been reported in several neurodegenerative dementias, but data in prion diseases are restricted to ex vivo and animal models. The present study identified significant miRNA expression pattern alterations in the frontal cortex and cerebellum of sporadic Creutzfeldt-Jakob disease (sCJD) patients. These changes display a highly regional and disease subtype-dependent regulation that correlates with brain pathology. We demonstrate that selected miRNAs are enriched in sCJD isolated Argonaute(Ago)-binding complexes in disease, indicating their incorporation into RNA-induced silencing complexes, and further suggesting their contribution to disease-associated gene expression changes. Alterations in the miRNA-mRNA regulatory machinery and perturbed levels of miRNA biogenesis key components in sCJD brain samples reported here further implicate miRNAs in sCJD gene expression (de)regulation. We also show that a subset of sCJD-altered miRNAs are commonly changed in Alzheimer's disease, dementia with Lewy bodies and fatal familial insomnia, suggesting potential common mechanisms underlying these neurodegenerative processes. Additionally, we report no correlation between brain and cerebrospinal fluid (CSF) miRNA-profiles in sCJD, indicating that CSF-miRNA profiles do not faithfully mirror miRNA alterations detected in brain tissue of human prion diseases. Finally, utilizing a sCJD MM1 mouse model, we analyzed the miRNA deregulation patterns observed in sCJD in a temporal manner. While fourteen sCJD-related miRNAs were validated at clinical stages, only two of those were changed at early symptomatic phase, suggesting that the miRNAs altered in sCJD may contribute to later pathogenic processes. Altogether, the present work identifies alterations in the miRNA network, biogenesis and miRNA-mRNA silencing machinery in sCJD, whereby contributions to disease mechanisms deserve further investigation.

Indexed as

RNA InterferenceTranscriptomeAdultAgedAged, 80 and overBrainCase-Control StudiesCreutzfeldt-Jakob SyndromeFemaleGene Expression ProfilingHumansMaleMicroRNAsMiddle AgedMicroRNAs

Identifiers

PMID29357384
PMCPMC5794191
OpenAlexW2784777634

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.